Prevail Clinical Research in Liberia

30/12/2024

P-CAG expressed gratitude to the PREVAIL Management for the donations of materials to two health facilities. The Liberian Health Authority in Duport Road and Margibi Counties.

30/12/2024

Season's Greetings from Prevail!

Dear Prevail Followers,
As we close out this year and prepare to embrace the new one, we want to take a moment to express our heartfelt gratitude to each one of you for being a part of the Prevail community. Your unwavering support, enthusiasm, and engagement have made this year truly special, and we couldn’t have done it without you!

This season, as we reflect on the challenges and triumphs we’ve shared, we are filled with hope and excitement for what lies ahead. The strength of our community and the resilience we see in you every day inspire us to continue striving for excellence, bringing you the very best we can offer.

In the spirit of the holidays, we wish you peace, joy, and a time of rest with loved ones. May this season bring warmth to your heart and joy to your home. As we step into the new year, we’re filled with anticipation for all the opportunities to grow, learn, and thrive together.

Thank you for your continued trust and for being a part of our journey. We are excited to share many more moments, milestones, and memories with you in the year to come!

Happy Holidays and a Happy New Year to you and yours! May 2025 bring you success, happiness, and all the things that make life truly wonderful.

With gratitude and excitement,
The Prevail Team

30/12/2024

SMC disseminates Neuro Sub study results to internal staff # #

The SMC Department of Prevail has distributed the Neuro Substudy to internal staff, starting at the Redemption Prevail Site. Sharing updates on study findings with internal Prevail staff will help them gain a better understanding of the outcomes from the various studies they are conducting within Prevail.

22/11/2024

International research consortium tackles Lassa vaccine development from concept to clinic. Dr. Mark Kieh presented the results of a CEPI supported study conducted across both the United States and Liberia.

Lassa virus (LASV) is a zoonotic viral hemorrhagic fever endemic to West Africa and classified as a priority pathogen by the World Health Organization (WHO). It causes an estimated 5,000 deaths and 300,000 illnesses annually, though the true burden is likely higher. An urgent need exists for a vaccine, as modeling studies suggest that a LASV vaccine could save thousands of lives and prevent up to US$128 million in societal costs over the next decade. With LASV’s geographic spread expanding due to climate change, urbanization, and other factors, vaccine development efforts are intensifying. The Coalition for Epidemic Preparedness Innovations (CEPI) is the leading funder of LASV vaccine research, supporting six candidates, four of which are in clinical trials. Among these, IAVI’s vesicular stomatitis virus (VSV)-based LASV vaccine is the furthest along. Leveraging the proven VSV platform used in Merck’s Ebola vaccine (Ervebo®), IAVI and its partners are advancing accessible vaccines for LASV and other priority diseases. At the recent TropMed conference, researchers shared updates on preclinical studies and Phase 1 clinical trial results for LASV vaccine candidates.

Dr. Mark Kieh, the principal investigator of the IAVI-sponsored Phase 1 clinical trial of IAVI's Lassa fever vaccine candidate at PREVAIL in Liberia, presented the results of a CEPI-supported study conducted across both the United States and Liberia.
The trial investigated the safety and immunogenicity of the vaccine candidate in two distinct cohorts. The findings demonstrated that the vaccine was well tolerated by participants in both locations. Additionally, the vaccine induced robust immune responses in both groups, with no safety concerns or adverse events identified throughout the trial.

These encouraging results provide critical evidence for the continued development of the vaccine, supporting its progression into Phase 2 clinical testing. The Phase 2 trials will further assess the candidate's efficacy, safety, and long-term immune responses in a larger population, moving closer to a potential solution for combating Lassa fever.
https://iamtropmed.org/blog/2024/11/18/international-research-consortium-tackles-lassa-vaccine-development-from-concept-to-clinic

12/11/2024

Lassa Fever affects thousands of people annually, particularly in West Africa, and can lead to severe health complications. A successful vaccine could save countless lives and help control outbreaks. The PREVAIL Social Mobilization Team provided education on the enrollment processes in the Sinkor communities.

Prevail is currently conducting a Lassa Fever Vaccine Study at the JFK Prevail Site.

05/11/2024

What Is the Importance of Conducting Biomedical Research on Infectious Diseases in the Community?

04/11/2024

# # What are Your thoughts on the infectious disease vaccine trial in your country?
How can we better support research initiatives in our communities?
Share your questions and insights below!

Join the conversation on vaccines trail during an infectious disease outbreak!

31/10/2024

Good morning to all our valued followers! We truly appreciate your support and opinions on our posts. Please don’t hesitate to reach out if you need further clarification or wish to engage with us regarding any content shared on our page.

As a vibrant research institution, Prevail is committed to conducting high-quality clinical and observational research in Liberia. Our headquarters is located at the AMD Dogliotti College of Medicine, next to St. Joseph Catholic Hospital.

We look forward to your continued engagement!

Call now to connect with business.

23/09/2024

PREVAIL Social Mobilization Hits The Sinkor Communities.

Lassa Fever affects thousands of people annually, particularly in West Africa, and can lead to severe health complications. A successful vaccine could save countless lives and help control outbreaks. The PREVAIL Social Mobilization Team provided education on the enrollment processes in the Sinkor communities.

vaccine phase 2a

20/09/2024

Celebrating Progress: P-CAG Completes Clinical Research Awareness Training!

The PREVAIL Community Advisory Group (P-CAG) has completed its Clinical Research Awareness Training. This crucial training has empowered P-CAG members with the knowledge and the necessary skills to distinguish between pre-clinical and Clinical Research, Observational studies, and Interventional trials. Facilitating this training, the PREVAIL Social Mobilization team (SMC), provided invaluable insights on study protocols, further enhancing the P-CAG's ability to actively engage in clinical research discussions and advocate for their community's rightful participation in biomedical research.

-CAG

19/09/2024

A Milestone Visit: U.S. Ambassador Mark Toner Explores PREVAIL's Vital Role in Liberia's Health Landscape

On yesterday, September 18, 2024, the Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) welcomed U.S. Ambassador Mark Toner to its JFK clinical research site in Monrovia. Accompanied by an esteemed delegation, including Minister of Health Dr. Louis Kpoto and JFK Hospital CEO Dr. Linda Birch, Ambassador Toner’s visit underscored the importance of collaborative efforts in combating infectious diseases.

Upon arrival, Ambassador Toner was greeted warmly by the PREVAIL Network Director, Dr. Soka Moses, and the dedicated PREVAIL clinical research team. The atmosphere was excited as the team shared updates on their groundbreaking scientific work since PREVAIL’s establishment in 2014. From pioneering trials on Ebola vaccines to the ongoing phase 2a studies on Lassa Fever, PREVAIL has become a beacon of hope and innovation in Liberia’s health sector.

The PREVAIL JFK clinical site, located within the Right Wing of the JFK Memorial Hospital, serves as a hub for vital clinical research. During the visit, Dr. Moses introduced the clinical team and highlighted the impressive progress made: four completed protocol studies, 11 ongoing protocol studies, and several more in the pipeline. This partnership between the U.S. and Liberia exemplifies the power of unity in addressing public health challenges.

Ambassador Toner admired PREVAIL’s commitment to improving health outcomes in Liberia. “Your work is not just about research; it’s about saving lives and building a healthier future for all Liberians,” he remarked, inspiring the team to continue their vital mission.

The atmosphere was filled with renewed energy and purpose as the visit concluded. The collaboration between PREVAIL and its partners promises to pave the way for innovative solutions to infectious diseases, fostering a healthier tomorrow.